|
1
|
Holdaway IM and Bowditch JV: Variation in
receptor status between primary and metastatic breast cancer.
Cancer. 52:479–485. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hull DF III, Clark GM, Osborne CK,
Chamness GC, Knight WA III and McGuire WL: Multiple estrogen
receptor assays in human breast cancer. Cancer Res. 43:413–416.
1983.PubMed/NCBI
|
|
3
|
Li BD, Byskosh A, Molteni A and Duda RB:
Estrogen and progesterone receptor concordance between primary and
recurrent breast cancer. J Surg Oncol. 57:71–77. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shimizu C, Fukutomi T, Tsuda H,
Akashi-Tanaka S, Watanabe T, Nanasawa T and Sugihara K: c-erbB-2
protein overexpression and p53 immunoreaction in primary and
recurrent breast cancer tissues. J Surg Oncol. 73:17–20. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kumar SK, Gupta N, Rajwanshi A, Joshi K
and Singh G: Immunochemistry for oestrogen receptor, progesterone
receptor and HER2 on cell blocks in primary breast carcinoma.
Cytopathology. 23:181–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
The World Health Organization:
Histological typing of breasr tumors. Neoplasma. 30:113–123.
1983.PubMed/NCBI
|
|
7
|
Sobin LH and Witterkind C: TNM
Classification of Malignant Tumours. 6th edition. Wiley; New York:
pp. 131–141. 2002
|
|
8
|
Allred DC, Harvey JM, Berardo M and Clark
GM: Prognostic and predictive factors in breast cancer by
immunohistochemical analysis. Mod Pathol. 11:155–168.
1998.PubMed/NCBI
|
|
9
|
Hammond ME, Hayes DF, Dowsett M, Allred
DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS,
Hayes M, et al: American Society of Clinical Oncology/College Of
American Pathologists guideline recommendations for
immunohistochemical testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 28:2784–2795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American Society of Clinical Oncology; College of
American Pathologists: American Society of Clinical
Oncology/College of American Pathologists guideline recommendations
for human epidermal growth factor receptor 2 testing in breast
cancer. J Clin Oncol. 25:118–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dowsett M, Nielsen TO, A'Hern R, Bartlett
J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, et
al: International Ki-67 in breast cancer working group: Assessment
of Ki67 in breast cancer: Recommendations from the International
Ki67 in breast cancer working group. J Natl Cancer Inst.
103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gerdes J, Lemke H, Baisch H, Wacker HH,
Schwab U and Stein H: Cell cycle analysis of a cell
proliferation-associated human nuclear antigen defined by the
monoclonal antibody Ki-67. J Immunol. 133:1710–1715.
1984.PubMed/NCBI
|
|
13
|
Niikura N, Liu J, Hayashi N, Mittendorf
EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN
and Ueno NT: Loss of human epidermal growth factor receptor 2
(HER2) expression in metastatic sites of HER2-overexpressing
primary breast tumors. J Clin Oncol. 30:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aitken SJ, Thomas JS, Langdon SP, Harrison
DJ and Faratian D: Quantitative analysis of changes in ER, PR and
HER2 expression in primary breast cancer and paired nodal
metastases. Ann Oncol. 21:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu S, Chia SK, Mehl E, Leung S, Rajput A,
Cheang MCU and Nielsen TO: Progesterone receptor is a significant
factor associated with clinical outcomes and effect of adjuvant
tamoxifen therapy in breast cancer patients. Breast Cancer Res
Treat. 119:53–61. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Purdie CA, Quinlan P, Jordan LB, Ashfield
A, Ogston S, Dewar JA and Thompson AM: Progesterone receptor
expression is an independent prognostic variable in early breast
cancer: A population-based study. Br J Cancer. 110:565–572. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishimura R, Osako T, Okumura Y, Tashima
R, Toyozumi Y and Arima N: Changes in the ER, PgR, HER2, p53 and
Ki-67 biological markers between primary and recurrent breast
cancer: Discordance rates and prognosis. World J Surg Oncol.
9:1312011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ibrahim T, Farolfi A, Scarpi E, Mercatali
L, Medri L, Ricci M, Nanni O, Serra L and Amadori D: Hormonal
receptor, human epidermal growth factor receptor-2, and Ki67
discordance between primary breast cancer and paired metastases:
Clinical impact. Oncology. 84:150–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang YF, Liao YY, Li LQ, Xie SR, Xie YF
and Peng NF: Changes in ER, PR and HER2 receptors status after
neoadjuvant chemotherapy in breast cancer. Pathol Res Pract.
209:797–802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keen JC and Davidson NE: The biology of
breast carcinoma. Cancer. 97 Suppl:825–833. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gong Y, Han EY, Guo M, Pusztai L and
Sneige N: Stability of estrogen receptor status in breast
carcinoma: A comparison between primary and metastatic tumors with
regard to disease course and intervening systemic therapy. Cancer.
117:705–713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Johnston SRD, Saccani-Jotti G, Smith IE,
Salter J, Newby J, Coppen M, Ebbs SR and Dowsett M: Changes in
estrogen receptor, progesterone receptor, and pS2 expression in
tamoxifen-resistant human breast cancer. Cancer Res. 55:3331–3338.
1995.PubMed/NCBI
|
|
23
|
Broom RJ, Tang PA, Simmons C, Bordeleau L,
Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM and
Clemons MJ: Changes in estrogen receptor, progesterone receptor and
Her-2/neu status with time: Discordance rates between primary and
metastatic breast cancer. Anticancer Res. 29:1557–1562.
2009.PubMed/NCBI
|
|
24
|
Lower EE, Glass EL, Bradley DA, Blau R and
Heffelfinger S: Impact of metastatic estrogen receptor and
progesterone receptor status on survival. Breast Cancer Res Treat.
90:65–70. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui X, Schiff R, Arpino G, Osborne CK and
Lee AV: Biology of progesterone receptor loss in breast cancer and
its implications for endocrine therapy. J Clin Oncol. 23:7721–7735.
2005. View Article : Google Scholar : PubMed/NCBI
|
